Comprehensive Genomic Profiling (CGP) advancing Precision Oncology

Comprehensive Genomic Profiling (CGP) is redefining standard of care in precision oncology enabling nucleotide-level resolution of a tumor’s complete genomic landscape in a single comprehensive assay. Unlike iterative multiple single-gene tests, FISH-PCR-single gene or small hotspot panels, CGP uses advanced technologies such as next-generation sequencing to detect a broad range of genetic alterations, including mutations, copy number changes, structural variants and large genomic signatures (TMB, MSI, HRD); helping identify actionable targets for tailored therapies and immunotherapies. Its application supports more accurate clinical decision-making, expands access to targeted treatments and clinical trials, and improves patient outcomes associated with longer progression-free and overall survival.

In this webinar, we will provide:

Technical Excellence:

• Overview of Illumina’s TruSight Oncology 500 v2:
  • DNA/RNA-based NGS solution
  • Reliable performance with limited tissue or liquid biopsy samples
  • Key workflow steps, analytical performance, and technical innovations
• Best practices for implementing CGP in routine

Expert Clinical insights:

• The role of clear guidelines and responsible implementation in integrating CGP into clinical practice
• How to fully realize the potential of precision medicine

Takeaway:

• A practical, dual-perspective understanding to successfully implement and utilize TSO 500 v2 in clinical and laboratory settings

Speakers

Anthony Alkhoury, PhD
Senior Technical Applications Scientist
Illumina Inc.

Dr. Anthony Alkhoury, is a Senior Technical Applications Scientist at Illumina, based in Dubai. He holds a double PhD in Toxicology, Genetics, and Biochemistry from the National Polytechnic Institute of Toulouse and Saint Joseph University in Beirut. Before joining Illumina in 2022, Anthony served as an Associate Lecturer and Researcher at the University of Paris, contributing to advancements in molecular biology and genomic sciences. In his current role, he supports the implementation of cutting‑edge sequencing technologies across the region and is deeply committed to Illumina’s mission of unlocking the power of the genome to improve human health.

Speakers

Boutros Maroun, MD, MSc, PhD
Senior Manager, Medical Affairs
Illumina Inc.

Dr. Boutros Maroun is a Senior Manager of Medical Affairs at Illumina for the EMEALA region. He holds an MD in Medicine and an MSc/PhD in Clinical Genetics and Genetic Counselling from University College London (UCL). Prior to joining Illumina, he served as a Clinical Genetics Liaison and GCC Regional Manager at Centogene, focusing on rare‑disease diagnostics. Dr. Maroun has extensive expertise in clinical genetics, oncogenetics, reproductive genetics, and genetic counselling. He has contributed to multiple advisory boards and supported the design of evidence‑generation studies and clinical trials. His current work centers on advancing clinical genomics adoption, generating real‑world evidence, raising awareness, and educating healthcare professionals on genetic testing across diverse clinical specialties.